The Latest “Buzz on the Street” Show: Featuring Pressure Biosciences Inc. (OTCQB: PBIO) Medical News

FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “Pressure BioSciences and The Steinbeis Centre Combine Efforts to Develop Revolutionary Method Based on Optimizing Disease-Fighting Antibodies”

Pressure BioSciences, Inc. (OTCQB: PBIO) a leader in the development and sale of pressure-based instruments and platform technologies to the life sciences and other industries worldwide, today announced a collaboration with The Steinbeis Centre for Biopolymer Analysis & Biomedical Mass Spectrometry, a world-renown German research organization.

Pressure BioSciences, Inc. is pressure-based platform solutions for the worldwide life sciences industry. Their products/services are based on three patented, pressure-enhanced platforms: Pressure Cycling Technology, Pressure Enabled Protein Manufacturing Technology, and Ultra Shear Technology.

The biotechnology market is one of the biggest industries in the world. However, despite being the largest sector globally, there are still various segments that haven’t been tapped into, presenting opportunities for many companies. Biotechnology is defined as technology to upgrade or modify the whole part of a biological system for human welfare. Processes within the industry include microbiology, genetic engineering, biochemistry, and many others which can help humans recover or potentially eliminate a medical condition with proper treatment. While there are many various types of medical conditions, the market is seeing a large demand for therapeutic and diagnostic solutions such as red biotechnology, recombinant technology, and DNA sequencing. According to data compiled by Variant Market Research, the global biotechnology market is projected to reach USD 726.8 Billion by 2025, as well as grow at a CAGR of 8.1% from 2017 to 2025. 

One sector in particular within the biotechnology industry has emerged within the top segments. The monoclonal antibody market has quickly become a strong and popular industry due to demand for personalized medicine. According to Grand View Research, the global monoclonal antibodies (mAbs) market was valued at approximately USD 85.4 Billion in 2015 and is expected to reach USD 138.6 Billion by 2024. The sector is mainly being driven by increasing R&D to develop mAbs, coupled with supportive government initiatives. mAbs provide patients with targeted therapies, which is important because patients vary in how their bodies accept the treatment or therapy. Additionally, using mAbs for therapeutic purposes, including fewer adverse effects, homogeneity, specificity, and large-scale production are also bolstering the market. “Antibody-derived biologics have become a major class of modern medicine, particularly in the fight against cancer and autoimmune diseases. Crucial to the successful translation of antibodies into therapies are highly efficient antibody discovery and cell line development pipelines,” said Frank F. Craig, Ph.D., Chief Executive Officer of Sphere Fluidics, “Biopharmaceutical organizations are under increasing pressure to streamline their antibody discovery and cell line development processes, with unmet needs for increased throughput, shortened timelines, reduced costs, and improved proof of monoclonality.”

For more information, please visit: Pressure Biosciences, Inc.

For more corporate news on Pressure Biosciences Inc., check out the Buzz on the Street

About Buzz on the Street: One of FinancialBuzz.com’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.

[popuppress id=”206261″]

4 Comments
  1. Michel Charbenneau 4 years ago
    Reply

    The National Center for Biotechnology Information conducted a study from 2017-2018 on cannabidiol users. More specifically, they asked a sample of 2,409 people why they were using CBD. There were 1,483 respondents who reported using CBD to treat at least one medical condition. Cannabis is definitely one of the markets to be in for the future advancements in the healthcare industry

    • Troy Zhou 4 years ago
      Reply

      The benefits of hemp are endless.This “billion dollar crop”offers great economic opportunity when cultivated on a large-scale.The jobs it can create can have a significant impact on reducing unemployment and related crimes. #cbd #Hemp

  2. Nancy McGill 4 years ago
    Reply

    The rare disease market leads Companies to Business Opportunities

    • Charles Norton 4 years ago
      Reply

      where there is demand, entrepreneurs & companies will look to supply

Leave a Comment